Analyzing ImmunoPrecise Antibodies (NASDAQ:IPA) & Bioxytran (OTCMKTS:BIXT)

ImmunoPrecise Antibodies (NASDAQ:IPAGet Free Report) and Bioxytran (OTCMKTS:BIXTGet Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.


This table compares ImmunoPrecise Antibodies and Bioxytran’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ImmunoPrecise Antibodies -60.23% -26.54% -18.36%
Bioxytran N/A N/A -2,861.84%

Valuation & Earnings

This table compares ImmunoPrecise Antibodies and Bioxytran’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunoPrecise Antibodies $15.61 million 1.67 -$19.98 million ($0.41) -2.41
Bioxytran N/A N/A -$4.28 million ($0.03) -4.05

Bioxytran has lower revenue, but higher earnings than ImmunoPrecise Antibodies. Bioxytran is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Comparatively, 70.0% of Bioxytran shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

ImmunoPrecise Antibodies has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Bioxytran has a beta of -0.74, indicating that its stock price is 174% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for ImmunoPrecise Antibodies and Bioxytran, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunoPrecise Antibodies 0 0 2 0 3.00
Bioxytran 0 0 0 0 N/A

ImmunoPrecise Antibodies currently has a consensus target price of $7.00, indicating a potential upside of 607.07%. Given ImmunoPrecise Antibodies’ higher probable upside, analysts plainly believe ImmunoPrecise Antibodies is more favorable than Bioxytran.


ImmunoPrecise Antibodies beats Bioxytran on 7 of the 12 factors compared between the two stocks.

About ImmunoPrecise Antibodies

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

About Bioxytran

(Get Free Report)

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with's FREE daily email newsletter.